Clinical efficacy of spironolactone for resistant hypertension: A meta analysis from randomized controlled clinical trials

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 7270-7278

  Guo, Hongyin ^a   Xiao, Qian ^a  

^a Department of Pharmacy People s Hospital of Wu Qing   (China)

Author keywords

Meta analysis; Resistant hypertension; Spironolactone

Indexed keywords

SPIRONOLACTONE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 84937047037     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. [1] Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertension 2013; 31: 3-15.
2. [2] Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)-study protocol. Hypertension 2011; 57: 1069-75.
3. [3] Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2010; 25: 514-23.
4. [4] Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31: 2094-2102.
5. [5] Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-9.
6. [6] Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the ren-in-angiotensin-aldosterone system. J Hyperten 2010; 28; 2329-35.
7. [7] Lane DA, Shah S, Beevers DG, Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-4.
8. [8] Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertens 2007; 25: 1105-87.
9. [9] Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-30.
10. [10] DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Statistics in medicine 1996;15:1237-48; discussion 49-52.
11. [11] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
12. [12] Krieger EM, Drager LF, Giorgi DM, Krieger JE, Pereira AC, Barreto-Filho JA, da Rocha Nogueira A, Mill JG. Resistant hypertension optimal treatment trial: a randomized controlled trial. Clin Cardiol 2014; 37: 1-6.
13. [13] De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-52.
14. [14] Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404.
15. [15] ReHOT Investigators, Krieger EM, Drager LF, Giorgi DM, Krieger JE, Pereira AC, Barreto-Filho JA, da Rocha Nogueira A, Mill JG. Resistant hypertension optimal treatment trial: A randomized controlled trial. Clin Cardiol 2014; 37: 1-6.
16. [16] Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124: 1046-58.
17. [17] Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45.
18. [18] Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-82.
19. [19] Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
20. [20] Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011; 22: 75-8.